Ronald G Gelbman insider trades: Haemonetics (HAE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ronald reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 11, 2019 | HAE | ↓ Sell | 16,926 | $118.26 | $2.0M | Direct | Nov 13, 2019 (2d) |
| Aug 8, 2019 | HAE | ↓ Sell | 1,696 | $134.15 | $228K | Direct | Aug 12, 2019 (4d) |
| Feb 15, 2019 | HAE | ↓ Sell | 8,196 | $86.52 | $709K | Direct | Feb 19, 2019 (4d) |
| Dec 14, 2018 | HAE | ↓ Sell | 4,329 | $103.02 | $446K | Direct | Dec 18, 2018 (4d) |
| Nov 16, 2017 | HAE | ↓ Sell | 5,440 | $56.69 | $308K | Direct | Nov 17, 2017 (1d) |
| Mar 24, 2017 | HAE | ↓ Sell10b5-1 | 8,580 | $40.00 | $343K | Direct | Apr 27, 2017 (34d) |
| Dec 12, 2016 | HAE | ↓ Sell | 5,683 | $40.30 | $229K | Direct | Dec 14, 2016 (2d) |
| Mar 5, 2015 | HAE | ↓ Sell | 7,707 | $44.76 | $345K | Direct | Mar 6, 2015 (1d) |
| Jun 12, 2014 | HAE | ↓ Sell | 9,184 | $34.00 | $312K | Direct | Jun 13, 2014 (1d) |
| Mar 6, 2014 | HAE | ↓ Sell | 12,000 | $36.17 | $434K | Direct | Mar 7, 2014 (1d) |
| Dec 13, 2012 | HAE | ↓ Sell | 11,310 | $40.07 | $453K | Direct | Dec 17, 2012 (4d) |
| Aug 23, 2012 | HAE | ↓ Sell | 6,000 | $71.90 | $431K | Direct | Aug 27, 2012 (4d) |
| May 17, 2012 | HAE | ↓ Sell | 2,473 | $71.49 | $177K | Direct | May 21, 2012 (4d) |
| Dec 23, 2010 | HAE | ↓ Sell | 6,000 | $64.22 | $385K | Direct | Dec 28, 2010 (5d) |
| May 11, 2010 | HAE | ↓ Sell | 9,000 | $57.02 | $513K | Direct | May 13, 2010 (2d) |
| Sep 18, 2009 | HAE | ↓ Sell | 6,000 | $55.78 | $335K | Direct | Sep 21, 2009 (3d) |
| Aug 2, 2006 | HAE | ↑ Buy | 4,442 | $44.99 | $200K | Direct | Aug 3, 2006 (1d) |
| Mar 13, 2006 | SERO | ↓ Sell | 1,725 | $24.52 | $42K | Direct | Mar 15, 2006 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other HAE insiders
Open-market trades in the last 12 months
About Ronald G Gelbman's insider trades
Ronald G Gelbman is a director at Haemonetics (HAE). Since Mar 13, 2006, Ronald has reported 1 open-market purchase worth $200K and 17 sales worth $7.7M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (4% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (19 filings), option exercises (15 filings), shares withheld for taxes (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every HAE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.